GMED— AI Stock Forecast & Price Targets
Published 8/13/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live GMED price forecast →
GMED shows strong fundamentals with robust revenue growth and healthy margins, but technicals indicate near-term volatility ahead of earnings. The current price is trading above the 50-day SMA with support at $84.75 and resistance at $96.00, while analyst consensus targets sit between $87.25 (base) and $103.23 (fair value).
Hold near-term as price approaches resistance at $96.00; invalidation below $84.75 (current support). Target $103.23 if technicals hold and earnings beat expectations.
Accumulate on dips to $87.25 (base target) with catalysts including Q4 revenue growth and FDA approval timelines for robotic platforms. Expect 10-15% upside over 6 months based on strong fundamentals and positive sentiment.
Long-term thesis hinges on sustained adoption of ExcelsiusGPS robotics platform; terminal value could reach $120 if procedural volume grows at 15% annually. Key risk is regulatory delays impacting new product approvals, which could cap growth to 8-10% annually.
Revenue growth is robust with Q2 2026 revenue of $789.6M (+6% YoY) driven by spine and trauma businesses, though Nevro sales declined. Gross margins remain strong at 68.97%, operating margins at 24.75%, and net margins at 19.19%. The balance sheet is solid with $595M in cash, low debt-to-equity (2.35), and a healthy current ratio of 4.62. Free cash flow has been consistently positive ($554M in Q2 2026) supporting R&D investment. However, the forward PEG ratio of 1.16 suggests growth is slightly overvalued relative to earnings potential.
The chart shows a bullish trend with price above the 50-day SMA (7.5% gain), breaking through resistance at $84.75 and approaching $96.00. The Kronos AI forecast band indicates a target of $103.23, but the model's directional accuracy for short-term horizons is low (bullish_prob 0.40). Support levels are at $84.75 (current price) and $77.974 (forecast), while resistance is at $96.00 (actual) and $103.23 (fair value). The RSI of 62.32 suggests moderate momentum without overbought conditions.
Recent news highlights a split narrative: analysts upgraded GMED to Zacks Rank #1 (Strong Buy) due to earnings strength, but fair value was cut from $107.42 to $103.23 reflecting softer growth expectations. The company reaffirmed 2026 revenue guidance and reported Q2 revenue of $789.6M (+6% YoY), with spine and trauma businesses offsetting declines in Nevro sales. However, the market is pricing in significant upside from robotics adoption, making execution risk paramount.
- ExcelsiusGPS robotic guidance system driving procedure volume growth (Q2 revenue up 6% YoY)
- Robotic platform adoption accelerating with spine and trauma businesses offsetting Nevro declines
- Regulatory delays impacting FDA approval timelines for new spinal devices
- Intense price competition from established medical device giants
- Macroeconomic headwinds limiting healthcare spending and margin expansion
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord